FDA’s New China Director Looks To Strengthen CFDA Ties
This article was originally published in PharmAsia News
August saw a change in the US FDA’s point person for China, as long-term FDA China director Chris Hickey left for a positon with Pfizer and Leigh Verbois took the charge with a mission to further develop strong ties with the China FDA amid the Chinese regulator’s hectic efforts to jumpstart regulatory reforms.
You may also be interested in...
As the China immuno-oncology sector becomes increasingly crowded, CStone teams up with an innovative US business partner to go global.
During a recent press briefing, health officials in China disclosed the country is poised to reach an annual production capacity of 610 million doses for coronavirus vaccines. But they said prices must be based on manufacturing costs and not driven by supply and demand.
With the threat of potentially hefty fines, China's newly passed Biosecurity Law will fundamentally change how the life science sector handles human genetic resources over years to come, legal experts say.